BioIntelliSense Launches Patented, FDA-cleared Pulse Oximetry (SpO2) Sensor Technology that Addresses Skin Pigmentation and Motion Monitoring Challenges

• Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion
• Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices

BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced the launch of its patented, FDA-cleared, pulse oximetery (SpO2 ) sensor chipset and integrated processing technology that accurately measures blood oxygen levels across the full range of light to very dark skin pigmentations, as well as during movement and activity. These capabilities represent a significant advancement in the field of oximetry which has historically been challenged by reduced accuracy during activity and in people with darker skin.1,2,3,4 BioIntelliSense’s pulse oximetry (SpO2 ) technology enables SpO2 monitoring anywhere, anytime, whether in clinical settings, at home, or beyond.

“Addressing these foundational skin pigmentation and motion challenges in the measurement of blood oxygen levels is transformative for the pulse oximetry category and allows for the democratization of this advanced technology across consumer and medical grade devices,” said James Mault, MD, founder and CEO of BioIntelliSense. “This is a significant milestone in providing clinically accurate SpO2 measurements across diverse patient populations which may contribute to improving healthcare equity.”